InSync in Circulation
This article was originally published in The Gray Sheet
Medtronic Impedance Diagnostics in Heart Failure Trial results demonstrating the efficacy of OptiVol fluid status monitoring technology appear in Aug. 9 edition of Circulation, the Journal of the American Heart Association. Featured on Medtronic's InSync Sentry cardiac resynchronization defibrillator, OptiVol is "shown to provide a warning of fluid accumulation in some patients an average of 15 days before heart failure symptoms appeared and 18 days before hospital admission," according to an Aug. 9 release...
You may also be interested in...
Medtronic believes that its foray into cardiac disease management with the Chronicle implantable hemodynamic monitor will differentiate its devices from competitors Guidant and St. Jude
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.